PF04518600

DRUG2 trials

Sponsors

Dana-Farber Cancer Institute, Pfizer

Conditions

Advanced MalignanciesFollicular LymphomaNSCLCOvarian CancerSolid TumorsUrothelial Cancer

Phase 1

Rituximab + Immunotherapy in Follicular Lymphoma

TerminatedNCT03636503

Dana-Farber Cancer InstituteFollicular Lymphoma

Start: 2018-10-30End: 2023-07-30Updated: 2025-02-06

Phase 3

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Active, not recruitingNCT05059522

PfizerAdvanced Malignancies, NSCLC, Ovarian Cancer +2

Start: 2021-09-29End: 2026-09-30Updated: 2025-06-25

Related Papers

Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial.

2024-05-1612 citations

A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.

2023-10-185 citations